Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
10 High priority Contraptions for Tech Aficionados - 2Tremendous Spelunking: Cool Caverns All over the Planet
- 3Hidden Island Cameras Capture Rare Tasmanian Species for the First Time Ever
- 4Defense Minister Katz moves to extend IDF service to 36 months
- 5Find the Standards of Viable Nurturing: Supporting Blissful and Strong Kids
- Vote In favor of Your Favored Kind Of Cheddar
- A Manual for Pick Viable Psychological well-being Backing Administrations In 2024
- The 3 little words TV fans can't stop obsessing over
- Key takeaways from Sen. Bill Cassidy's interview on 'Face the Nation' with Margaret Brennan
- Share your number one city visit transport that leaves a mark on the world wake up!
- Medtronic has 'significant firepower' for multiple acquisitions, executives say
- I traveled to 13 countries in 2025. This small island nation surprised me the most.
- Figure out How to Analyze Medical attendant Compensation Patterns Across Different Specializations
- What is the Significant Tech Expertise to Master Today?
